Kathleen S. Capps - Aug 26, 2025 Form 3 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Executive Director, Accounting & Controller; Exhibit 24 Power of Attorney filed herewith.
Signature
/s/ Matthew Kowalsky as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Aug 26, 2025
Transactions value $
$0
Form type
3
Date filed
9/8/2025, 06:01 PM
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Capps Kathleen S. Executive Director, Accounting & Controller; Exhibit 24 Power of Attorney filed herewith. C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN /s/ Matthew Kowalsky as attorney-in-fact 2025-09-08 0002085127

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ENTA Common Stock 5.83K Aug 26, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 497 $29.68 Direct F2
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 2.67K $30.00 Direct F2
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 5.95K $48.52 Direct F2
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 7K $81.20 Direct F2
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 8.13K $63.35 Direct F2
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 5.4K $43.57 Direct F2
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 4.91K $75.33 Direct F3
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 3.48K $45.00 Direct F4
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 5.25K $8.99 Direct F5
holding ENTA Stock Option (right to buy) Aug 26, 2025 Common Stock 5.51K $8.83 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying unvested restricted stock units ("RSUs") granted under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle as follows: (i) 293 RSUs will vest and settle on December 1, 2025, (ii) 812 RSUs will vest and settle in two substantially equal annual installments beginning on December 4, 2025, (iii) 1,968 RSUs will vest and settle in three substantially equal annual installments beginning on December 4, 2025, and (iv) 2,756 RSUs will vest and settle in four substantially equal annual installments beginning on December 1, 2025.
F2 100% of the shares subject to the option are fully vested and exercisable.
F3 Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).
F4 Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022).
F5 Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).
F6 Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

Remarks:

Executive Director, Accounting & Controller; Exhibit 24 Power of Attorney filed herewith.